CLINICAL RESEARCH
Amino-Terminal Pro-Brain Natriuretic Peptide, Renal Function, and Outcomes in Acute Heart Failure
Redefining the Cardiorenal Interaction?
Roland R.J. van Kimmenade, MD, PhD*,
James L. Januzzi, Jr, MD ,*,
Aaron L. Baggish, MD,
John G. Lainchbury, MD ,
Antoni Bayes-Genis, MD, PhD ,
A. Mark Richards, MD, PhD and
Yigal M. Pinto, MD, PhD*
* Department of Cardiology, University Hospital Maastricht, Maastricht, the Netherlands
Department of Cardiology, Massachusetts General Hospital, Boston, Massachusetts
Christchurch Cardioendocrine Research Group, Christchurch School of Medicine and Health Science, Christchurch, New Zealand
Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Manuscript received January 10, 2006;
revised manuscript received May 3, 2006,
accepted June 5, 2006.
* Reprint requests and correspondence: Dr. James L. Januzzi, Jr., Massachusetts General Hospital, Yawkey 5800, 55 Fruit Street, Boston, Massachusetts 02114. (Email: jjanuzzi{at}partners.org).
OBJECTIVES: We sought to study the individual and integrative role of amino-terminal pro-brain natriuretic peptide (NT-proBNP) and parameters of renal function for prognosis in heart failure.
BACKGROUND: Amino-terminal pro-BNP and renal impairment both predict death in patients with heart failure. Worsening of renal function in heart failure even defines the "cardiorenal syndrome."
METHODS: Seven hundred twenty subjects presenting with acute heart failure from 4 university-affiliated medical centers were dichotomized according to NT-proBNP concentration and baseline glomerular filtration rate. In addition, patients were divided according to changes in renal function. The primary end point was 60-day mortality.
RESULTS: The combination of a glomerular filtration rate (GFR) <60 ml/min/1.73 m2 with an NT-proBNP >4,647 pg/ml was the best predictor of 60-day mortality (odds ratio 3.46; 95% confidence interval 2.13 to 5.63). Among subjects with an NT-proBNP above the median, those with a GFR <60 ml/min/1.73 m2 or a creatinine rise  0.3 mg/dl had the worst prognosis, whereas in subjects with a NT-proBNP below the median, prognosis was not influenced by either impaired renal function at presentation or the development of renal impairment during admission.
CONCLUSIONS: The combination of NT-proBNP with measures of renal function better predicts short-term outcome in acute heart failure than either parameter alone. Among heart failure patients, the objective parameter of NT-proBNP seems more useful to delineate the "cardiorenal syndrome" than the previous criteria of a clinical diagnosis of heart failure.
|
Abbreviations and Acronyms
| | BNP = brain natriuretic peptide | | GFR = glomerular filtration rate | | HF = heart failure | | ICON = International Collaborative on NT-proBNP | | MDRD = Modified Diet in Renal Disease | | NT-proBNP = amino-terminal pro-brain natriuretic peptide |
|
This article has been cited by other articles:
|
|
|
|
 
L. B. Daniels, G. A. Laughlin, P. Clopton, A. S. Maisel, and E. Barrett-Connor
Minimally Elevated Cardiac Troponin T and Elevated N-Terminal Pro-B-Type Natriuretic Peptide Predict Mortality in Older Adults: Results From the Rancho Bernardo Study
J. Am. Coll. Cardiol.,
August 5, 2008;
52(6):
450 - 459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C H J Michielsen, J. A Bakker, R. R J V. Kimmenade, Y. M Pinto, and M. P V. Dieijen-Visser
The diagnostic value of serum and urinary NT-proBNP for heart failure
Ann Clin Biochem,
July 1, 2008;
45(4):
389 - 394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. W. Waldo, J. Beede, S. Isakson, S. Villard-Saussine, J. Fareh, P. Clopton, R. L. Fitzgerald, and A. S. Maisel
Pro-B-Type Natriuretic Peptide Levels in Acute Decompensated Heart Failure
J. Am. Coll. Cardiol.,
May 13, 2008;
51(19):
1874 - 1882.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R.J. van Kimmenade, Y. Pinto, and J. L. Januzzi Jr
When renal and cardiac insufficiencies intersect: is there a role for natriuretic peptide testing in the 'cardio-renal syndrome'?
Eur. Heart J.,
December 2, 2007;
28(24):
2960 - 2961.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Witteles, D. Kao, D. Christopherson, K. Matsuda, R. H. Vagelos, D. Schreiber, and M. B. Fowler
Impact of Nesiritide on Renal Function in Patients With Acute Decompensated Heart Failure and Pre-Existing Renal Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
J. Am. Coll. Cardiol.,
November 6, 2007;
50(19):
1835 - 1840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schou, F. Gustafsson, C. N. Kistorp, P. Corell, A. Kjaer, and P. R. Hildebrandt
Effects of Body Mass Index and Age on N-Terminal Pro Brain Natriuretic Peptide Are Associated with Glomerular Filtration Rate in Chronic Heart Failure Patients
Clin. Chem.,
November 1, 2007;
53(11):
1928 - 1935.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. deFilippi, S. L. Seliger, S. Maynard, and R. H. Christenson
Impact of Renal Disease on Natriuretic Peptide Testing for Diagnosing Decompensated Heart Failure and Predicting Mortality
Clin. Chem.,
August 1, 2007;
53(8):
1511 - 1519.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure
Circulation,
July 31, 2007;
116(5):
e99 - e109.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Richards
Natriuretic Peptides: Update on Peptide Release, Bioactivity, and Clinical Use
Hypertension,
July 1, 2007;
50(1):
25 - 30.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. C. Fonarow, W. F. Peacock, C. O. Phillips, M. M. Givertz, M. Lopatin, and for the ADHERE Scientific Advisory Committee and I
Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure
J. Am. Coll. Cardiol.,
May 15, 2007;
49(19):
1943 - 1950.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
